Carcinogenesis, Vol. 21, No. 4, 533-541,
April 2000
© 2000 Oxford University Press
Commentary |
Threshold mechanisms and site specificity in chromium(VI) carcinogenesis
Department of Health Sciences, Section of Hygiene and Preventive Medicine, University of Genoa, via A. Pastore 1, I-16132 Genoa, Italy
Ten years have elapsed since the International Agency for Research on Cancer (IARC) evaluated the carcinogenicity of chromium and chromium compounds. Further studies performed during the last decade have provided further epidemiological, experimental and mechanistic data which support the IARC conclusions. A wealth of results indicate that, at variance with chromium(0) and chromium(III), chromium(VI) can induce a variety of genetic and related effects in vitro. The lack of carcinogenicity of chromium(0) and chromium(III) compounds in experimental animals is well established, and only a minority of animal carcinogenicity data with chromium(VI) compounds were positive (30 out of 70, i.e. 42.9%). Moreover, most positive studies used administration routes which do not mimic any human exposure and by-pass physiological defense mechanisms. Typically, positive results were only obtained at implantation sites and at the highest dose tested. Exposure to chromium(VI) has been known for more than a century to be associated with induction of cancer in humans. Carcinogenicity requires massive exposures, as is only encountered in well defined occupational settings, and is site specific, being specifically targeted to the lung and, in some cases, to the sinonasal cavity. Increased death rates for cancers at other sites, which were occasionally reported in some epidemiological studies, were almost invariably not statistically significant, and inconsistent (being counterbalanced by other studies which apparently showed decreased rates for the same cancers). As we recently quantified in human body compartments, chromium(VI) can be reduced in body fluids and non-target cells, which results in its detoxification, due to the poor ability of chromium(III) to cross cell membranes. In target cells, chromium(VI) tends to be metabolized by a network of mechanisms leading to generation of reduced chromium species and reactive oxygen species, which will result either in activation or in detoxification depending on the site of the intracellular reduction and its proximity to DNA. When introduced by the oral route, chromium(VI) is efficiently detoxified upon reduction by saliva and gastric juice, and sequestration by intestinal bacteria. If some chromium(VI) is absorbed by the intestine, it is massively reduced in the blood of the portal system and then in the liver. These mechanisms explain the lack of genotoxicity, carcinogenicity, and induction of other long-term health effects of chromium (VI) by the oral route. Within the respiratory tract, chromium(VI) is reduced in the epithelial-lining fluid, pulmonary alveolar macrophages, bronchial tree and peripheral lung parenchyma cells. Hence, lung cancer can only be induced when chromium(VI) doses overwhelm these defense mechanisms. The efficient uptake and reduction of chromium(VI) in red blood cells explains its lack of carcinogenicity at a distance from the portal of entry into the body. All experimental and epidemiological data, and the underlying mechanisms, point to the occurrence of thresholds in chromium(VI) carcinogenesis.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  C. Viti, F. Decorosi, A. Mini, E. Tatti, and L. Giovannetti Involvement of the oscA gene in the sulphur starvation response and in Cr(VI) resistance in Pseudomonas corrugata 28 Microbiology, January 1, 2009; 155(1): 95 - 105. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Reynolds and A. Zhitkovich Cellular vitamin C increases chromate toxicity via a death program requiring mismatch repair but not p53 Carcinogenesis, July 1, 2007; 28(7): 1613 - 1620. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Reynolds, L. Stoddard, I. Bespalov, and A. Zhitkovich Ascorbate acts as a highly potent inducer of chromate mutagenesis and clastogenesis: linkage to DNA breaks in G2 phase by mismatch repair Nucleic Acids Res., January 28, 2007; 35(2): 465 - 476. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Azad, V. Vallyathan, L. Wang, V. Tantishaiyakul, C. Stehlik, S. S. Leonard, and Y. Rojanasakul S-Nitrosylation of Bcl-2 Inhibits Its Ubiquitin-Proteasomal Degradation: A NOVEL ANTIAPOPTOTIC MECHANISM THAT SUPPRESSES APOPTOSIS J. Biol. Chem., November 10, 2006; 281(45): 34124 - 34134. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Quievryn, J. Messer, and A. Zhitkovich Lower mutagenicity but higher stability of Cr-DNA adducts formed during gradual chromate activation with ascorbate Carcinogenesis, November 1, 2006; 27(11): 2316 - 2321. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Kirpnick-Sobol, R. Reliene, and R. H. Schiestl Carcinogenic Cr(VI) and the Nutritional Supplement Cr(III) Induce DNA Deletions in Yeast and Mice. Cancer Res., April 1, 2006; 66(7): 3480 - 3484. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. H. Duffus Chemical speciation terminology: chromium chemistry and cancer Mineralogical Magazine, October 1, 2005; 69(5): 557 - 562. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Danadevi, R. Rozati, B.S. Banu, and P. Grover Genotoxic evaluation of welders occupationally exposed to chromium and nickel using the Comet and micronucleus assays Mutagenesis, January 1, 2004; 19(1): 35 - 41. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R S Luippold, K A Mundt, R P Austin, E Liebig, J Panko, C Crump, K Crump, and D Proctor Lung cancer mortality among chromate production workers Occup. Environ. Med., June 1, 2003; 60(6): 451 - 457. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. A. Howd Can We Protect Everybody from Drinking Water Contaminants? International Journal of Toxicology, September 1, 2002; 21(5): 389 - 395. [Abstract] [PDF]
|
|
|
|
|
|
M. Huvinen, A. Makitie, H. Jarventaus, H. Wolff, T. Stjernvall, A. Hovi, A. Hirvonen, R. Ranta, M. Nurminen, and H. Norppa Nasal cell micronuclei, cytology and clinical symptoms in stainless steel production workers exposed to chromium Mutagenesis, September 1, 2002; 17(5): 425 - 429. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. D'Agostini, A. Izzotti, C. Bennicelli, A. Camoirano, E. Tampa, and S. De Flora Induction of apoptosis in the lung but not in the liver of rats receiving intra-tracheal instillations of chromium(VI) Carcinogenesis, April 1, 2002; 23(4): 587 - 593. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. J. O'Flaherty, B. D. Kerger, S. M. Hays, and D. J. Paustenbach A Physiologically Based Model for the Ingestion of Chromium(III) and Chromium(VI) by Humans Toxicol. Sci., April 1, 2001; 60(2): 196 - 213. [Abstract] [Full Text] [PDF]
|
|